Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.
Authors
Apostolia Maria Tsimberidou
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX
Apostolia Maria Tsimberidou, Chad Stewart, Carsten Reinhardt, Hong Ma, Steffen Walter, Toni Weinschenk, Amir A. Jazaeri, Borje Andersson, Patrick Hwu, Cassian Yee, Harpreet Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses
Sub Track
Cell Therapies
Clinical Trial Registration Number
NCT02876510
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr TPS77)
DOI
10.1200/JCO.2018.36.5_suppl.TPS77
Abstract #
TPS77
Poster Bd #
M8
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.
First Author: Apostolia Maria Tsimberidou
Poster
2024 ASCO Annual Meeting
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.
First Author: Sajeve Samuel Thomas
Poster
2023 ASCO Annual Meeting
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.
First Author: Benjamin L. Schlechter
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.
First Author: Benjamin L. Schlechter